GoAI
Get started
BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp.

BCTX

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$4.07

+$0.14 · +3.56%

Aug 21, 4:00 PM ET

BCTX company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

38

Expensive

Momentum

42

Neutral

Sentiment

57

Mixed

Risk resilience

24

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

BriaCell Therapeutics Corp. is an immuno-oncology biotechnology company primarily focused on developing innovative immunotherapies to combat cancer. The firm's leading experimental drug, Bria-IMT, is currently undergoing Phase I/IIa clinical investigation. This crucial study evaluates its effectiveness when utilized in conjunction with immune checkpoint inhibitors for treating breast cancer. Beyond its flagship program, BriaCell has forged a collaborative research and development partnership with the National Cancer Institute (NCI). This alliance is dedicated to progressing Bria-OTS, a personalized immunotherapy designed for advanced breast cancer patients, and BriaDx, a proprietary diagnostic assay. The company's main offices are situated in West Vancouver, Canada.

Industry
Biotechnology
Sector
Healthcare
Headquarters
CA
CEO
William V. Williams
Listed since
Mar 14, 2012
Employees
16

Market position

Day range

Current $4.07

52-week range

Current $4.07

Open
$3.99
Previous close
$3.93
Volume
150.44K
0.82× average
Average volume
184.2K
Average daily volume
Market cap
35.41M USD
Beta
1.52
Market reference 1
50-day average
$3.4254
+18.82% above average
200-day average
$5.1236
-20.56% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
-374.14K USD
P/E (TTM)
-0.33×
P/B (TTM)
1.21×
P/S (TTM)
0×
EV / EBITDA
0.01×
Earnings yield
-259.67%
Free cash flow yield
-278.02%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-148.44%
Return on assets
-122.60%
Return on invested capital
-155.30%

Financial health

Debt / equity
0×
Current ratio
5.01×
Altman Z-score
-2.63
Piotroski F-score
2 of 9

Financial statements

Income trends

Operating income

−37.73M USD-13.17%

Net income

−36.49M USD-661.35%
Income trends across reported periods−1.5M USD−14.67M USD−27.85M USD−41.03M USDOperating income, FY2021: −8.72M USDOperating income, FY2022: −19.61M USDOperating income, FY2023: −31.08M USDOperating income, FY2024: −33.34M USDOperating income, FY2025: −37.73M USDNet income, FY2021: −17.27M USDNet income, FY2022: −34.42M USDNet income, FY2023: −27.11M USDNet income, FY2024: −4.79M USDNet income, FY2025: −36.49M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −8.72M USD. Operating income FY2022 −19.61M USD. Operating income FY2023 −31.08M USD. Operating income FY2024 −33.34M USD. Operating income FY2025 −37.73M USD. Net income FY2021 −17.27M USD. Net income FY2022 −34.42M USD. Net income FY2023 −27.11M USD. Net income FY2024 −4.79M USD. Net income FY2025 −36.49M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold147.89K USD82.57K USD15.53K USD15.14K USD15.58K USD
Gross profit−147.89K USD−82.57K USD−15.53K USD−15.14K USD−15.58K USD
Research and development29.5M USD27.19M USD20.48M USD10.29M USD2.53M USD
Selling, general, and administrative8.08M USD6.15M USD10.6M USD9.32M USD6.19M USD
Operating expenses37.58M USD33.34M USD31.08M USD19.61M USD8.72M USD
Interest income166.38K USD283.61K USD1.2M USD173.86K USD4.02K USD
Interest expense51.29K USD——1.24K USD100.22K USD
Depreciation and amortization147.89K USD83.93K USD20.39K USD19.59K USD19.07K USD
Operating income−37.73M USD−33.34M USD−31.08M USD−19.61M USD−8.72M USD
Net income−36.49M USD−4.79M USD−27.11M USD−34.42M USD−17.27M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
45%
5 beats, 6 misses, 0 met estimates
Average EPS surprise
-1684.62%
11 comparable reports
Latest EPS result
-0.99

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.06-11.91-23.76-35.61Q4 '24BeatQ4 '24MissQ1 '25MissQ2 '25BeatQ4 '25BeatQ4 '25MissQ1 '26BeatQ2 '26No estimate
Q4 2024, reported Oct 28, 2024: actual -0.07, estimate -0.52, surprise +86.54%, Beat. Q4 2024, reported Dec 16, 2024: actual -32.98, estimate -0.3, surprise -10893.33%, Miss. Q1 2025, reported Mar 12, 2025: actual -23.3, estimate -19.4, surprise -20.10%, Miss. Q2 2025, reported Jun 16, 2025: actual -1.64, estimate -17.6, surprise +90.68%, Beat. Q4 2025, reported Oct 27, 2025: actual -10.49, estimate -12.11, surprise +13.38%, Beat. Q4 2025, reported Dec 11, 2025: actual -4.35, estimate -3.28, surprise -32.62%, Miss. Q1 2026, reported Mar 10, 2026: actual -2.58, estimate -4.84, surprise +46.69%, Beat. Q2 2026, reported Jun 9, 2026: actual -0.99, estimate —, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Recent analyst actions

1 institution

BCTX news

globenewswire.com

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancer Bria-PROS+ is BriaCell's next generation personalized immunotherapy for…

Read source
globenewswire.com

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company…

Read source
globenewswire.com

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

PHILADELPHIA and VANCOUVER, British Columbia, July 15, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company…

Read source
globenewswire.com

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

PHILADELPHIA and VANCOUVER, British Columbia, July 07, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company…

Read source
globenewswire.com

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

PHILADELPHIA and VANCOUVER, British Columbia, June 25, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company…

Read source
globenewswire.com

BriaCell Therapeutics Announces Closing of Offering

PHILADELPHIA & VANCOUVER, British Columbia, June 02, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company…

Read source

Corporate actions

Corporate action history

Stock split

Effective Aug 25, 2025

1:10

Stock split

Effective Jan 29, 2025

1:15

Stock split

Effective Jan 2, 2020

1:300

Stock split

Effective Dec 3, 2014

307:1,000

BCTX peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research BCTX

research.disclaimer